Zyban

ApprovedSmall molecule

UUS Department of Veterans Affairs

Zyban is one of 104 small molecule programs targeting Nicotine Dependence. It is currently in Approved.

Indications

Total Trials

Active Trials

103

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nicotine DependenceActive, not recruiting

Lung CancerActive, not recruiting

Smoking CessationActive, not recruiting

Nicotine DependencePhase 1

Active, not recruiting

Lung CancerApproved

Active, not recruiting

Smoking CessationPhase 2

Active, not recruiting

Competition

Competitive Landscape

686 competitors in Lung Cancer

#DrugCompanyPhaseTrials

Zyban

UUS Department of Veterans Affairs

Approved

1 2

Tecentriq

Roche

Preclinical

9 3

Libtayo

Regeneron

Preclinical

3 4

Vizimpro

Pfizer

Preclinical

3 5

Talzenna

Pfizer

Preclinical

2 6

Folvite

Immunotherapy

5 8

Paclitaxel and Carboplatin

Bristol-Myers Squibb

Preclinical

2 9

Rilotumumab

Amgen

Preclinical

2 10

Acupan

YYonsei University

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Smoking Cessation1 trial

Combination Bupropion / Varenicline for Smoking Cessation in Male Smokers

Completed·—·Phase 2·NCT01806779·376 enrolled

Nicotine Dependence1 trial

Brain Reaction to Treatment of Nicotine Dependence

Completed·UUS Department of Veterans Affairs·Phase 1·NCT00108173·104 enrolled

Lung Cancer1 trial

Bio-behavioral Lung Cancer Prevention Program

Completed·NNational Institutes of Health (NIH)·Phase 4·NCT00322205·555 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Zyban. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zyban compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zyban. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — US Department of Veterans Affairs company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUS Department of Veterans Affairs

Zyban

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Smoking Cessation1 trial

Nicotine Dependence1 trial

Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News